{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:24:20Z","timestamp":1792268660302,"version":"4.4.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"\n Importance<\/jats:title>\n \n Cyclin-dependent kinase (CDK) 4\/6 inhibitors combined with endocrine therapy (ET) are now considered the standard treatment regimen for hormone receptor\u2013positive (HR\n +<\/jats:sup>\n ) and\n ERBB2<\/jats:italic>\n (formerly\n HER2<\/jats:italic>\n )\u2013negative (\n ERBB2<\/jats:italic>\n \u2212<\/jats:sup>\n ) advanced breast cancer (ABC). Tibremciclib (BPI-16350), a novel CDK4\/6 inhibitor, has demonstrated favorable tolerability and promising antitumor activity as a monotherapy or combined with fulvestrant among patients with HR\n +<\/jats:sup>\n \/\n ERBB2<\/jats:italic>\n \u2212<\/jats:sup>\n ABC in a phase 1 trial. Further investigations are necessary to assess the efficacy and safety of tibremciclib.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To compare tibremciclib plus fulvestrant and placebo plus fulvestrant in terms of efficacy and safety among patients with HR\n +<\/jats:sup>\n \/\n ERBB2<\/jats:italic>\n \u2212<\/jats:sup>\n ABC who exhibited disease progression after ET.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n The TIFFANY trial was a double-blind, placebo-controlled, phase 3 randomized clinical trial of patients with HR\n +<\/jats:sup>\n \/\n ERBB2<\/jats:italic>\n \u2212<\/jats:sup>\n ABC who had experienced progression while receiving prior ET and had received no more than 1 line of chemotherapy. This trial was conducted at 69 Chinese centers between May 25, 2022, and April 25, 2023. The data cutoff date for this analysis was March 31, 2024.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomly assigned to receive tibremciclib (400 mg, orally, once daily) plus fulvestrant or placebo plus fulvestrant at a 2:1 ratio until disease progression, death, or treatment discontinuation for various reasons.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was investigator-assessed progression-free survival (PFS), and the secondary end points included the objective response rate, overall survival, and safety.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 274 female patients (median [IQR] age, 53.0 [46.0-60.0] years) were randomly assigned to receive tibremciclib plus fulvestrant (184 [67.2%]) or placebo plus fulvestrant (90 [32.8%]). Among these patients, 144 PFS events occurred (80 in the tibremciclib arm and 64 in the placebo arm), with a median follow-up of 12.9 months for both arms. Tibremciclib plus fulvestrant significantly improved PFS compared with placebo plus fulvestrant (median, 16.5 months [95% CI, 12.8-16.6] vs 5.6 months [95% CI, 4.5-9.2]; hazard ratio, 0.37; 95% CI, 0.27-0.52;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). In patients with measurable disease, tibremciclib plus fulvestrant achieved an objective response rate of 45.6% (95% CI, 37.6%-53.7%) compared with 12.9% (95% CI, 6.1%-23.0%) in the placebo arm (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The most common grade 3 or higher treatment-emergent adverse events in the tibremciclib vs placebo arm were neutropenia (15.2% vs 5.6%, respectively), anemia (12.0% vs 4.4%, respectively), and hypokalemia (12.0% vs 0%, respectively). No drug-related deaths occurred in the tibremciclib arm, and 1 death occurred in the placebo arm.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n The results of this randomized clinical trial suggest that tibremciclib plus fulvestrant was associated with statistically significant and clinically meaningful improvements in PFS compared with placebo plus fulvestrant. Furthermore, tibremciclib plus fulvestrant demonstrated a manageable safety profile in patients with HR\n +<\/jats:sup>\n \/\n ERBB2<\/jats:italic>\n \u2212<\/jats:sup>\n ABC who experienced progression while receiving prior ET.\n <\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05433480<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.2092","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:30:50Z","timestamp":1753975850000},"page":"1055","source":"Crossref","is-referenced-by-count":5,"title":["Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor\u2013Positive and\n ERBB2<\/i>\n -Negative Advanced Breast Cancer After Endocrine Therapy"],"prefix":"10.1001","volume":"11","author":[{"given":"Zhonghua","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Shandong Cancer Hospital, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[{"name":"Breast Medical Oncology Department, Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Chemotherapy Department II, Weihai Municipal Hospital, Weihai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yichang Central People\u2019s Hospital, Yichang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangshun","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Xingtai People\u2019s Hospital, Xingtai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijuan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Central Hospital of Yongzhou, Yongzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfang","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Tianjin Medical University Cancer Center Institute and Hospital, Tianjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sichuan Cancer Hospital, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[{"name":"Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshuai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The first Affiliated Hospital of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, Betta Pharmaceuticals Co, Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Medicine, Betta Pharmaceuticals Co, Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Betta Pharmaceuticals Co, Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Betta Pharmaceuticals Co, Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, Betta Pharmaceuticals Co, Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Medicine, Betta Pharmaceuticals Co, Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieming","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medicine, Betta Pharmaceuticals Co, Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi250035r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"coi250035r2","first-page":"688","article-title":"The natural history of hormone receptor-positive breast cancer.","volume":"26","author":"Lim","year":"2012","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"coi250035r3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"25","key":"coi250035r5","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline.","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250035r6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.5306\/wjco.v5.i5.990","article-title":"Overcoming endocrine resistance in metastatic breast cancer: current evidence and future directions.","volume":"5","author":"Milani","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"4","key":"coi250035r7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition.","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"coi250035r8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.4161\/cc.6.6.3988","article-title":"RB in breast cancer: at the crossroads of tumorigenesis and treatment.","volume":"6","author":"Bosco","year":"2007","journal-title":"Cell Cycle"},{"issue":"Suppl 1","key":"coi250035r9","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S0960-9776(19)31118-X","article-title":"Endocrine therapy resistance: new insights.","volume":"48","author":"Lei","year":"2019","journal-title":"Breast"},{"issue":"1","key":"coi250035r10","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1038\/s41467-021-25422-9","article-title":"Co-targeting CDK4\/6 and AKT with endocrine therapy prevents progression in CDK4\/6 inhibitor and endocrine therapy-resistant breast cancer.","volume":"12","author":"Alves","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"coi250035r11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer.","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"24","key":"coi250035r12","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3.","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"coi250035r13","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy.","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi250035r14","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med"},{"key":"coi250035r19","doi-asserted-by":"publisher","first-page":"e13051","DOI":"10.1200\/JCO.2023.41.16_suppl.e13051","article-title":"BPI-16350, a novel promising CDK4\/6 inhibitor for HR+\/HER2- metastatic breast cancer (MBC): results from a phase I study.","volume":"41","author":"Zhang","year":"2023","journal-title":"JCO"},{"key":"coi250035r20","doi-asserted-by":"publisher","first-page":"S349","DOI":"10.1016\/j.annonc.2024.08.259","article-title":"320MO tibremciclib (BPI-16350) plus fulvestrant in patients with HR+\/HER2-advanced breast cancer after progressing on endocrine therapy: a randomized, multicenter, double-blind, phase III study.","volume":"35","author":"Hu","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"coi250035r21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"coi250035r22","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study.","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"coi250035r23","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.annonc.2022.07.268","article-title":"Dalpiciclib plus fulvestrant in HR+\/HER2- advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial.","volume":"33","author":"Zhang","year":"2022","journal-title":"Ann Oncol"},{"key":"coi250035r4","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): breast cancer, version 2.2017. Accessed August 27, 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx"},{"key":"coi250035r15","unstructured":"US Food and Drug Administration. Palbociclib highlights of prescribing information. Accessed September 6, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207103s007lbl.pdf"},{"key":"coi250035r16","unstructured":"US Food and Drug Administration. Ribociclib highlights of prescribing information. Accessed January 30, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209092s001lbl.pdf"},{"key":"coi250035r17","unstructured":"US Food and Drug Administration. Abemaciclib highlights of prescribing information. Accessed September 6, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208855s000lbl.pdf"},{"key":"coi250035r18","unstructured":"US Food and Drug Administration. Fulvestrant highlights of prescribing information. Accessed January 30, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021344s035lbl.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2837083\/jamaoncology_tao_2025_oi_250035_1757953480.90922.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:18:36Z","timestamp":1758208716000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2837083"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.2092","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}